Frank Mottola - Feb 22, 2023 Form 4/A - Amendment Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Sr VP, Quality, GMP Oper. & IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Feb 22, 2023
Transactions value $
-$11,147
Form type
4/A - Amendment
Date filed
4/12/2023, 05:00 PM
Date Of Original Report
Feb 24, 2023
Previous filing
Feb 21, 2023
Next filing
Feb 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Award $0 +750 +8.55% $0.00 9.52K Feb 22, 2023 Direct F1
transaction SUPN Common Stock Tax liability -$11.1K -289 -3.04% $38.57 9.23K Feb 22, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Units Disposed to Issuer $0 -750 -25% $0.00 2.25K Feb 22, 2023 Common Stock 750 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 576 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F3 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F4 These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023.